Bristow Robert E, Peiretti Michele, Gerardi Melissa, Zanagnolo Vanna, Ueda Stefanie, Diaz-Montes Teresa, Giuntoli Robert L, Maggioni Angelo
The Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Medical Institutions, MD 21287, USA.
Gynecol Oncol. 2009 Aug;114(2):173-7. doi: 10.1016/j.ygyno.2009.05.004. Epub 2009 May 31.
To describe the operative technique and associated clinical outcomes of patients undergoing rectosigmoid colectomy as a component of secondary cytoreductive surgery for recurrent ovarian cancer.
Consecutive patients undergoing rectosigmoid colectomy for recurrent epithelial ovarian cancer between 1/01 and 12/07 were retrospectively identified and clinical data abstracted from the medical record. The surgical technique, associated morbidity, and clinical outcomes are described.
Fifty-six patients were identified. The median age at secondary surgery was 56 years; 78.6% had advanced-stage disease at initial diagnosis; 69.6% had grade 3 tumors; 73.2% had serous histology. Complete cytoreduction to no gross residual disease was achieved in 85.7% of cases. Concurrent distal ureterectomy/partial cystectomy was required in 8 cases (14.3%). The median number of regional cytoreductive procedures outside the pelvis was 1 (range=0-4). A stapled coloproctostomy was performed in 98.2% of patients; a protective colostomy/ileostomy was constructed in 7 cases (12.5%), and one patient (1.8%) underwent end colostomy. The median EBL was 500 cm(3) and the median operative time was 225 min. Blood transfusion was administered to 48.2% of patients. Post-operative morbidity occurred in 23.2% of patients, with a bowel fistula rate of 5.4% and a mortality rate of 1.8%. The median LOS was 9 days. Post-operative platinum-based chemotherapy was administered in 73.2% of patients. The median overall survival time from secondary surgery was 38.4 months.
Rectosigmoid colectomy can contribute significantly to a maximal cytoreductive surgical effort for recurrent ovarian cancer. Despite technical differences, including a frequent requirement for resection of the distal urinary tract, morbidity is comparable to rectosigmoid colectomy performed for primary cytoreduction and the associated survival outcome appears favorable.
描述乙状结肠直肠切除术作为复发性卵巢癌二次减瘤手术一部分的手术技术及相关临床结果。
回顾性确定2001年1月至2007年12月期间因复发性上皮性卵巢癌接受乙状结肠直肠切除术的连续患者,并从病历中提取临床数据。描述手术技术、相关并发症及临床结果。
共确定56例患者。二次手术时的中位年龄为56岁;78.6%在初次诊断时为晚期疾病;69.6%为3级肿瘤;73.2%为浆液性组织学类型。85.7%的病例实现了完全减瘤至无肉眼残留疾病。8例(14.3%)患者需要同时行远端输尿管切除术/部分膀胱切除术。盆腔外区域减瘤手术的中位次数为1次(范围=0 - 4次)。98.2%的患者行吻合器结肠直肠吻合术;7例(12.5%)患者行保护性结肠造口术/回肠造口术,1例患者(1.8%)行末端结肠造口术。中位估计失血量为500 cm³,中位手术时间为225分钟。48.2%的患者接受了输血。23.2%的患者发生术后并发症,肠瘘发生率为5.4%,死亡率为1.8%。中位住院时间为9天。73.2%的患者术后接受了铂类化疗。二次手术后的中位总生存时间为38.4个月。
乙状结肠直肠切除术可显著助力复发性卵巢癌的最大程度减瘤手术。尽管存在技术差异,包括经常需要切除远端尿路,但并发症发生率与为初次减瘤而进行的乙状结肠直肠切除术相当,且相关生存结果似乎良好。